US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Release time：2024-05-01 06:19:01 Source：Culture Curves news portal
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
- Previous：WWF calls for global treaty to protect high seas
- Next：Xi Sends Condolences to Iranian President over Serious Terror Attacks
Related articles
- Ecuador embroiled in diplomatic backlash after police break into Mexican embassy
- Nation favored magnet for foreign investors
- Chengdu emerges as drone hub in western China
- Green hydrogen, ammonia, ethanol highlighted for nation's carbon reduction
- Sweden raises policy rate to 2.5 pct to curb inflation
- Xinhua Headlines: Key Meeting Sets Tone on China's Financial Development
- Online outlets prove boon for smaller retailers
- Alibaba to invest $640m in HK's entertainment industry
- G20 Summit to be held in Bali, Indonesia
- Cruise ship industry poised for new golden era
- Roundup: Establishment of diplomatic ties with China applauded across Honduras
- World Smile Day marked across China
- Xi Meets President of Brazil's Chamber of Deputies
- China to keep track of EU actions against Chinese businesses
- Young giant panda Qing Ci dies from rare intestinal disorder
- China's securities regulator tightens delisting regulation
- Fueled by visa
- Guizhou gears up in computing
- Sweden raises policy rate to 2.5 pct to curb inflation
- Traditional Double Sixth Festival celebrated in SW China's Guizhou
Random recommendation
- Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Curves news portal sitemap